Access in all areas? A round up of developments in market access and health technology assessment: part 3

Abstract

In this latest update, we explore some of the key updates in market access over recent months including the UK’s voluntary scheme for branded medicines pricing, access and growth (VPAG), the first drugs funded by the Innovative Medicines Fund in the UK and the Direct Access Scheme in France, and, finally, the new Institute for Clinical and Economic Review (ICER) value assessment framework in the USA.

Keywords

• canadian drug agency
• direct access scheme
• health technology assessment
• health technology management
• icer
• innovative medicines fund
• market access
• value assessment framework
• vpag